Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
MICROB-PREDICT co-organised Falk Symposium on Alcoholic Liver Disease
From 27-28 January 2022, consortium members Prof. Aleksander Krag (OUH) and Prof. Rajiv Jalan (UCL) as well as members of the scientific and ethical advisory board (SEAB), including Dr. Vijay Shah (Mayo Clinic) and Prof. Bernd Schnabl (UCSD) presented and discussed the newest research results and pressing questions regarding the treatment and recovery from alcoholic liver disease, while MICROB-PREDICT coordinator Prof. Jonel Trebicka (GUF), who had co-organised the online symposium, served as chairman of Session II on "Alcoholic hepatitis, liver failure, and systemic disturbance" and the poster session.More news
4th General Assembly Meeting, Mallorca
Our 4th GA meeting, taking place from 15-18 March 2022 in Mallorca has been successfully completed.
The first 1.5 days were reserved for our first MICROB-PREDICT paper-writing workshop. 35 scientists from all over Europe discussed 12 papers about ACLF and microbiome in four different places face-to-face and virtual at the same time!
The other days were dedicated to hear further updates and results from our different work packages. With 54 participants joining on-site and almost 20 participants remotely the meeting was a great success. Thank you all for taking part!